ATE544762T1 - Calcium rezeptor modulatoren - Google Patents

Calcium rezeptor modulatoren

Info

Publication number
ATE544762T1
ATE544762T1 AT03736701T AT03736701T ATE544762T1 AT E544762 T1 ATE544762 T1 AT E544762T1 AT 03736701 T AT03736701 T AT 03736701T AT 03736701 T AT03736701 T AT 03736701T AT E544762 T1 ATE544762 T1 AT E544762T1
Authority
AT
Austria
Prior art keywords
receptor modulators
calcium receptor
calcium
modulators
receptor
Prior art date
Application number
AT03736701T
Other languages
English (en)
Inventor
Michael Kelly
Shimin Xu
Ning Xi
Robert Townsend
David Semin
Chiara Ghiron
Thomas Coutler
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE544762T1 publication Critical patent/ATE544762T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/22Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/80[b, c]- or [b, d]-condensed
    • C07D209/82Carbazoles; Hydrogenated carbazoles
    • C07D209/86Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/80[b, c]- or [b, d]-condensed
    • C07D209/82Carbazoles; Hydrogenated carbazoles
    • C07D209/88Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/041,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
AT03736701T 2002-05-23 2003-05-23 Calcium rezeptor modulatoren ATE544762T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38327002P 2002-05-23 2002-05-23
US10/444,945 US7176322B2 (en) 2002-05-23 2003-05-22 Calcium receptor modulating agents
PCT/US2003/016384 WO2003099814A1 (en) 2002-05-23 2003-05-23 Calcium receptor modulating agents

Publications (1)

Publication Number Publication Date
ATE544762T1 true ATE544762T1 (de) 2012-02-15

Family

ID=29586996

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03736701T ATE544762T1 (de) 2002-05-23 2003-05-23 Calcium rezeptor modulatoren

Country Status (12)

Country Link
US (1) US7176322B2 (de)
EP (1) EP1509518B1 (de)
JP (1) JP4642461B2 (de)
AR (1) AR040095A1 (de)
AT (1) ATE544762T1 (de)
AU (1) AU2003237235B2 (de)
CA (1) CA2485685C (de)
ES (1) ES2378759T3 (de)
MX (1) MXPA04011469A (de)
PL (1) PL375559A1 (de)
TW (1) TW200410960A (de)
WO (1) WO2003099814A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6908935B2 (en) * 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
WO2005065050A2 (ja) * 2003-12-25 2005-07-21 Asahi Kasei Pharma Corporation 2環化合物
GB0400781D0 (en) * 2004-01-14 2004-02-18 Novartis Ag Organic compounds
JP4629036B2 (ja) 2004-05-28 2011-02-09 田辺三菱製薬株式会社 アリールアルキルアミン化合物及びその製法
US7361789B1 (en) 2004-07-28 2008-04-22 Amgen Inc. Dihydronaphthalene compounds, compositions, uses thereof, and methods for synthesis
CN101175724B (zh) * 2005-05-19 2011-12-07 安斯泰来制药有限公司 吡咯烷衍生物或其盐
EP1937233B1 (de) * 2005-09-02 2013-01-09 Amgen Inc. Modulierung des darmflüssigkeitsgleichgewichtes mittels calcimimetika
WO2007100880A1 (en) * 2006-02-28 2007-09-07 Amgen Inc. Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors
AU2007230724B2 (en) * 2006-03-23 2014-01-30 Amgen Inc. Methods and compositions for making and using polymorphs of cinacalcet
WO2007124465A2 (en) * 2006-04-20 2007-11-01 Amgen Inc. Stable emulsion formulations
ES2449340T3 (es) 2007-03-30 2014-03-19 Amgen Inc. Compuestos calcimiméticos para su uso en el tratamiento de trastornos intestinales
WO2009051718A2 (en) * 2007-10-15 2009-04-23 Amgen Inc. Calcium receptor modulating agents
WO2009155527A2 (en) * 2008-06-19 2009-12-23 Progenics Pharmaceuticals, Inc. Phosphatidylinositol 3 kinase inhibitors
WO2010104882A1 (en) 2009-03-10 2010-09-16 Amgen Inc. Methods of modulating sperm motility
WO2010136035A2 (en) 2009-05-27 2010-12-02 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
US8765676B2 (en) 2009-05-27 2014-07-01 Leo Pharma A/S Calcium sensing receptor modulating compounds and pharmaceutical use thereof
CN102958907A (zh) 2010-06-30 2013-03-06 利奥制药有限公司 钙敏感受体激动化合物的新多晶型
US8946474B2 (en) 2010-06-30 2015-02-03 Leo Pharma A/S Polymorphic form of a calcimimetic compound
WO2012069402A1 (en) 2010-11-26 2012-05-31 Leo Pharma A/S Substituted cyclopentyl - azines as casr- active compounds
EP2643292A1 (de) 2010-11-26 2013-10-02 Leo Pharma A/S Casr-aktive verbindungen
EP2643290A1 (de) 2010-11-26 2013-10-02 Leo Pharma A/S Casr-aktive verbindungen
JP2014508104A (ja) 2010-11-26 2014-04-03 レオ ファーマ アクティーゼルスカブ カルシウム感知受容体活性化合物
IN2015MN00421A (de) * 2012-08-27 2015-09-04 Lupin Ltd
GB201217330D0 (en) 2012-09-28 2012-11-14 Univ Cardiff Therapeutic for treating inflammatory lung disorders
CN113416187B (zh) 2013-03-14 2024-07-19 奥斯菲治疗有限公司 促进骨生长的烷基胺骆驼蓬碱衍生物
JP2022504011A (ja) 2018-08-14 2022-01-13 オステオーク インコーポレイティド ピロロ-ジピリジン化合物
JP2021535091A (ja) 2018-08-14 2021-12-16 オステオーク インコーポレイティド フルオロβ−カルボリン化合物

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US444946A (en) * 1891-01-20 Method of electric welding
US143212A (en) * 1873-09-23 Improvement in attachments for ladies work-tables
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
DE69433714T2 (de) 1991-08-23 2005-03-31 NPS Pharmaceuticals, Inc., Salt Lake City Kalzium - receptor aktive arylalkylamine
US6001884A (en) 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6031003A (en) 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6011068A (en) 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
JP2728564B2 (ja) 1991-08-23 1998-03-18 エヌピーエス・ファーマシウティカルズ・インコーポレイテッド カルシウム受容体活性化分子
KR100296899B1 (ko) 1993-02-23 2001-10-24 쉘비 칼베르그 모르스 칼슘수용체활성분자
AU3414295A (en) 1994-08-19 1996-03-14 Nps Pharmaceuticals, Inc. Methods and compounds active at metabotropic glutamate receptors useful for treatment of neurological disorders and diseases
AU3642795A (en) 1994-09-27 1996-04-19 Merck & Co., Inc. Endothelin receptor antagonists for the treatment of emesis
CZ290670B6 (cs) 1994-10-21 2002-09-11 Nps Pharmaceuticals, Inc. Sloučeniny modulující receptory anorganických iontů a farmaceutický prostředek, který je obsahuje
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
ATE400653T1 (de) 1995-07-26 2008-07-15 Astrazeneca Ab Chimäre rezeptoren und verfahren zur identifizieren verbindungen mit einem aktivität als metabotropischen glutamatrezeptoren sowie verwendung solcher verbindungen in der behandlung von neurologischer erkrankungen und neurologischenstörrungen
IL126458A (en) 1996-04-09 2004-06-20 Nps Pharma Inc Calcium receptor inhibiting calcilytic compounds
PT907631E (pt) 1996-05-01 2003-10-31 Nps Pharma Inc Compostos inorganicos activos como receptores de ioes
KR100771092B1 (ko) 1996-07-08 2007-10-30 기린 파마 가부시끼가이샤 칼슘 수용체 활성 화합물
PT966436E (pt) 1997-02-21 2003-03-31 Bayer Ag Arilsulfonamidas e analogos e sua aplicacao para o tratamento de doencas neurodegenerativas
UY24949A1 (es) 1997-04-08 2001-04-30 Smithkline Beecham Corp Compuestos calcilíticos
WO1999001439A1 (en) 1997-07-03 1999-01-14 Du Pont Pharmaceuticals Company Aryl-and arylamino-substituted heterocycles as corticotropin releasing hormone antagonists
JP2002522532A (ja) 1998-08-12 2002-07-23 スミスクライン・ビーチャム・コーポレイション カルシウム分解化合物
CA2347092A1 (en) 1998-10-14 2000-04-20 Ortho-Mcneil Pharmaceutical, Inc. 1,2-disubstituted cyclopropanes
DK1157005T3 (da) 1999-02-24 2005-02-14 Hoffmann La Roche 3-phenylpyridinderivater og anvendelsen deraf som NK-1-receptorantagonister
TR200102490T2 (tr) 1999-02-24 2001-12-21 F.Hoffmann-La Roche Ag Fenil ve piridinil türevleri
EP1074539B1 (de) 1999-08-04 2007-10-17 Sumitomo Chemical Company, Limited Verfahren zur Herstellung von optisch aktiver 3,3,3-Trifluor-2-hydroxy-2-methylpropionsäure und deren Salze
FR2800735B1 (fr) 1999-11-09 2002-02-01 Centre Nat Rech Scient Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation
ES2254077T3 (es) 1999-12-18 2006-06-16 Wella Aktiengesellschaft Derivados 2-aminoalquil-1,4-diaminobenceno y su utilizacion para el teñido de fibras.
FR2809396B1 (fr) 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
DE10028402A1 (de) 2000-06-13 2001-12-20 Merck Patent Gmbh Pyridin-2-yl-aminoalkycarbonylglycyl-beta-alanin und Derivate
US6900232B2 (en) 2000-06-15 2005-05-31 Pharmacia Corporation Cycloalkyl alkanoic acids as integrin receptor antagonists
JP2004517851A (ja) 2000-12-27 2004-06-17 バイエル アクチェンゲゼルシャフト 甲状腺受容体のリガンドとしてのインドール誘導体
CA2448160A1 (en) * 2001-05-25 2002-12-05 Queen's University At Kingston Heterocyclic beta-amino acids and their use as anti-epileptogenic agents

Also Published As

Publication number Publication date
EP1509518A1 (de) 2005-03-02
WO2003099814A1 (en) 2003-12-04
AU2003237235A1 (en) 2003-12-12
US7176322B2 (en) 2007-02-13
JP4642461B2 (ja) 2011-03-02
TW200410960A (en) 2004-07-01
EP1509518B1 (de) 2012-02-08
JP2005530811A (ja) 2005-10-13
US20040077619A1 (en) 2004-04-22
CA2485685C (en) 2010-02-02
PL375559A1 (en) 2005-11-28
AU2003237235B2 (en) 2007-08-23
ES2378759T3 (es) 2012-04-17
CA2485685A1 (en) 2003-12-04
MXPA04011469A (es) 2005-02-14
AR040095A1 (es) 2005-03-16

Similar Documents

Publication Publication Date Title
ATE544762T1 (de) Calcium rezeptor modulatoren
DE60325025D1 (de) Modulatoren des vanilloidrezeptors
ATE557036T1 (de) Ox40 rezeptor bindende agenzien
DE50212417D1 (de) Knochenverankerungselement
AU2003290778A8 (en) Non-steroidal farnesoid x receptor modulators
DE60327767D1 (de) Tricyclische steroidhormonkernrezeptor-modulatoren
DE602004026540D1 (de) Kurbelwellenmomentmodulator
PL382706A1 (pl) Związek modulujący receptor wapnia i jego zastosowanie
DE60336314D1 (de) Substituierte indole
PL376438A1 (en) Calcium receptor modulating arylalkylamines
NO20051042L (no) Pyrimidylsulfonamidderivater som kemokinreseptormodulatorer
DE50311534D1 (de) Gewebeband-einrichtung
ATE456558T1 (de) Gabanerge modulatoren
DE50206709D1 (de) Knochenplatte
DE60335913D1 (de) Ghrelin-analoga
DE60327447D1 (de) Pflaster
DE50312759D1 (de) Oszillationsantrieb
DE602004018247D1 (de) Modulator
DE50313381D1 (de) Oszillationsantrieb
FI20020258A0 (fi) Kiristyselin
DK1495030T3 (da) Ikke-steroidale progesteronreceptormodulatorer
DE50307407D1 (de) Strömungsbremse
NO20022892L (no) Forankringssystem
DE50300379D1 (de) Oszillationsantrieb
DE60322635D1 (de) Geschalteter Modulator